Compound hub · Ipamorelin
Ipamorelin side effects: what the trials, the FDA and the TGA recorded
The searches for this page found numbers on adverse events from only one clinical trial. It was a placebo-controlled Phase 2 trial of up to 7 days in 114 analysed bowel-surgery patients (Beck et al., 2014). Regulator reviews also describe individual reports. In those 114 patients, low potassium, sleeplessness and high blood sugar at discharge were more common with the drug than with placebo. Two patients given the drug died after surgical complications. The FDA said it is unclear whether the drug played a part. One small trial after surgery cannot separate a drug effect from surgery (Beck et al., 2014; FDA 2024).
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
A side-effect list sounds like a verdict. The records for ipamorelin are not one. They are short, and they come from a narrow group of people. The regulators who reviewed them said so in plain terms. This page is part of the ipamorelin hub. It sets out what each source recorded. It marks every gap.
None of this is a safety rating. A trial of patients who had just had bowel surgery says little about anyone else. A regulator's concern is not the same as a measured harm. For the science behind the compound, read what ipamorelin is and what studies found.
Key facts
| Human trials with safety data | One Phase 2 surgery trial, NCT00672074 (114 analysed). A second Phase 2 trial, NCT01280344, shows no posted results on ClinicalTrials.gov (checked 14 October 2026). |
|---|---|
| Recorded more often than placebo | In the Phase 2 trial in 114 bowel-surgery patients: low potassium in 12.5 percent given the drug against 3.4 percent given placebo. Sleeplessness in 10.7 against 5.2 percent. High blood sugar at discharge in 14.3 against 8.6 percent. One small trial after surgery cannot separate a drug effect from surgery (Beck et al., 2014; FDA 2024). |
| Deaths in the trial | In the Phase 2 trial in 114 patients, two patients given the drug died after surgical complications. The FDA said it is unclear whether the drug played a part (FDA 2024, on Beck et al., 2014). |
| FDA adverse event reports | Two non-serious reports for products containing ipamorelin, through 30 September 2023. The FDA said it cannot draw conclusions from them (FDA 2024). |
| FDA category 2 (503B) | Ipamorelin acetate, added 29 September 2023; GHRP-6 added the same day (FDA category 2 page, current as of 22 April 2026). |
| FDA toxicity findings | No studies of repeated exposure, genetic damage or cancer found. The FDA called the nonclinical studies 'too limited in scope and duration' (FDA 2024). |
| FDA advisory committee | 29 October 2024: 0 yes, 12 no, 1 abstain on adding ipamorelin to the 503A list. Advice only (FDA final summary minutes). |
| Australian status | Schedule 4 and Appendix D, clause 5, item 25, October 2026 Poisons Standard (read 14 October 2026). |
| Records checked | 14 October 2026 |
Evidence limits
What do the safety records for ipamorelin not show?
The safety records opened for this page do not show how ipamorelin behaves over months or years. They do not show it in healthy people. They do not show it in any group outside bowel-surgery patients. The one trial with adverse-event data analysed 114 patients over up to 7 days. Its authors called it small, with many kinds of underlying illness (Beck et al., International Journal of Colorectal Disease, 2014). The FDA found the nonclinical toxicity studies 'too limited in scope and duration'. It found no safety data for the subcutaneous route (FDA briefing document, 29 October 2024). Two adverse event reports reached the FDA. The agency said it cannot draw conclusions from them (FDA 2024).
The FDA's summary covers Gobburu et al. (1999). That study used eight healthy men at each of five infusion rates. It measured hormone levels. It did not state whether adverse events occurred. That reporting gap does not show that none occurred (FDA 2024).
A 2020 review of this class of compounds names the same limit. It describes a 'paucity of data' on their clinical effects. It ran no new trial (Sinha et al., Translational Andrology and Urology, 2020).
What side effects have been recorded in people given ipamorelin?
The placebo-controlled Phase 2 trial had 114 analysed bowel-surgery patients. At least one treatment-emergent adverse event occurred in 87.5 percent of patients given ipamorelin and 94.8 percent given placebo. The authors said most events were mild to moderate. They said the events were mostly linked to surgery or to the disease itself (Beck et al., 2014). Nausea, vomiting and abdominal swelling were the most common events. They were similar between groups (Beck et al., 2014). Three things were more common with ipamorelin than with placebo. These were low potassium (12.5 against 3.4 percent), sleeplessness (10.7 against 5.2 percent) and high blood sugar at discharge (14.3 against 8.6 percent) (Beck et al., 2014; FDA 2024). Three patients in each arm stopped treatment because of an adverse event (FDA 2024, on Beck et al.). One small trial after surgery cannot separate a drug effect from surgery.
In the 2014 trial, 114 patients had just had bowel surgery. The authors concluded that ipamorelin was well tolerated over up to 7 days. They said it did not differ significantly from placebo on the key and secondary efficacy measures. That conclusion is the authors' own. It applies to postoperative patients only (Beck et al., 2014).
The comparison table below sets out the full set of figures the FDA reported from this trial.
What serious adverse events did the trial record?
In the Phase 2 trial in 114 patients, serious adverse events occurred in 10 patients (17.9 percent) given the drug. They occurred in 9 patients (15.5 percent) given placebo. They included infection, anastomotic leak (where a surgical join between bowel ends fails) and readmission within 30 days. One small trial after surgery cannot separate a drug effect from surgery (FDA 2024, on Beck et al., 2014). Two patients given the drug died. Both had bowel resection for colon cancer and then complications. The FDA said it is unclear whether the deaths were related to the drug (FDA 2024). The FDA said the deaths weighed in its safety concern. So did the higher rates of low potassium and high blood sugar. It was still unclear whether the drug played a part in the deaths (FDA 2024).
The FDA's account of the trial gives the main causes of death. They were high potassium (in a patient with aortic clots), sepsis, a perforated ulcer, and kidney failure with sepsis (in a patient with pneumonia). It says most serious events occurred after patients had finished therapy. A trial of 114 patients cannot separate a drug effect from the surgery (FDA 2024).
What did the FDA conclude about the safety of compounded ipamorelin?
The FDA concluded in its August 2024 review that compounding with ipamorelin may raise safety concerns. The review lists the adverse events from the one surgery trial. It flags a risk that impurities or clumping in the peptide could cause an immune response. It notes that ipamorelin contains unnatural amino acids, which make it hard to describe fully. It found no safety data for the subcutaneous route. It could not conclude that ipamorelin avoids concerns seen with approved products that raise growth hormone. These include glucose intolerance and diabetes (FDA briefing document, 29 October 2024).
The review also says that ipamorelin acts on the ghrelin receptor. So it may have behavioural reinforcing properties that can contribute to addiction. It may also negatively affect reproductive health and pregnancy outcomes. These are the FDA's concerns from how the drug works and from nonclinical data. They are not harms measured in a trial (FDA 2024).
Two adverse event reports reached the FDA through 30 September 2023. One followed a nasal spray product. It involved increased tear production and headache. The report assumed they were related to a product quality issue (FDA 2024). The other followed a compounded product that also contained sermorelin. It involved joint pain that the FDA could not link to ipamorelin specifically (FDA 2024).
The FDA's advisory committee voted on 29 October 2024 on adding ipamorelin to the 503A bulks list. The vote was 0 yes, 12 no, 1 abstain (FDA final summary minutes). Is ipamorelin legal in Australia? covers the regulatory records.
What does the FDA say about ipamorelin, GHRP-6 and similar compounds?
The FDA's category 2 page lists ipamorelin acetate and GHRP-6 for the 503B pathway. Both were added on 29 September 2023. For GHRP-6 the FDA names a risk of immune reaction. It also names 'potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity'. For ipamorelin acetate the FDA names the immune risk and unnatural amino acids. It also names a published study. In it, patients with gut movement problems got ipamorelin into a vein. The trial figures from the FDA's briefing document are in the sections above. The FDA adds that it lacks information on harm by other routes (FDA category 2 page, 22 April 2026).
The same page lists GHRP-2 and ibutamoren mesylate. The FDA lists them as category 2 substances. This page reports no trial result for either one (FDA category 2 page). The tesamorelin, sermorelin, GHRP-6 and ipamorelin comparison sets the class side by side. A listing here is a safety flag from a regulator. It is not a measured rate of harm.
Is ipamorelin safer than HGH?
No comparison of the safety of ipamorelin with human growth hormone was found in the sources read for this page. So none supports calling it safer. A pig study found that ipamorelin released growth hormone without raising ACTH or cortisol above the GHRH level. The abstract gives no count. This is an animal result. It does not show a human result. It is not a safety finding in people (Raun et al., European Journal of Endocrinology, 1998). The FDA says no data show that ipamorelin avoids concerns seen with approved products that raise growth hormone. These include glucose intolerance and diabetes (FDA briefing document, 29 October 2024). In 2015 the TGA delegate noted that misusing these substances is thought to carry risks like those of misusing growth hormone (TGA, March 2015).
In eight healthy men at each of five infusion rates, growth hormone rose to a single short peak. Then it fell to negligible levels. The study measured hormone levels, not safety (Gobburu et al., 1999). The FDA flagged that long exposure might run down growth hormone stores in people with partial deficiency. This concern comes from that model. It is not harm that anyone measured (FDA 2024). Neither point compares safety with the hormone itself.
What are the side effects of tesamorelin, and is there safety data on a tesamorelin and ipamorelin blend?
No safety data on a tesamorelin and ipamorelin blend were found. A PubMed search on 14 October 2026 returned seven records for both names. All were review articles. ClinicalTrials.gov listed no study of both. Tesamorelin has its own record. The Egrifta WR label, revised March 2025, lists warnings for neoplasms (new tissue growth), raised IGF-1, fluid retention, glucose intolerance, hypersensitivity and reactions where the medicine is given. Its most commonly reported adverse reactions include joint pain, pain in the limbs and peripheral swelling. It was first approved in the US in 2010 (Egrifta WR label, March 2025). A 26-week trial in 412 adults with HIV found no significant difference from placebo in adverse events. More people on tesamorelin withdrew because of one. That result applies to tesamorelin alone in that group. It does not apply to a blend (Falutz et al., New England Journal of Medicine, 2007).
The evidence is uneven. Tesamorelin has a 26-week trial in 412 adults with HIV (Falutz et al., 2007). It also has an approved label for one condition (Egrifta WR label, March 2025). The published ipamorelin trial with adverse-event numbers followed 114 bowel-surgery patients for up to 7 days (Beck et al., 2014). Neither record covers the two together. A combined product also raises the questions about making and purity that the FDA asked of compounded peptides. How tesamorelin and ipamorelin differ sets out the comparison.
What does PubMed show about ipamorelin clinical trial safety?
A PubMed search for ipamorelin on 14 October 2026 returned 55 records. Only two are indexed as clinical trials: the 1999 volunteer study and the 2014 surgery trial. The FDA's review says Gobburu et al. (1999), a hormone-level study in healthy male volunteers, did not state whether adverse events occurred. That reporting gap does not show safety (FDA 2024). Beck et al. (2014), a trial in 114 patients, is the only source of adverse-event rates found in these searches. A second Phase 2 trial, NCT01280344, enrolled 320 patients. It shows no posted results on ClinicalTrials.gov. So its safety findings are unpublished in the sources opened for this page (PubMed and ClinicalTrials.gov, 14 October 2026).
The rest of the PubMed record is animal work, laboratory studies and reviews. A 2026 review states that the clinical evidence for ipamorelin remains minimal. It ran no new trial (Dominikowski et al., Frontiers in Endocrinology, 2026). The record can change. The search date above is the one that applies.
What adverse events has the TGA recorded for unapproved peptide products?
The TGA's advisory of 13 April 2026 lists problems that people reported about unapproved peptide products as a group. These include severe allergic reactions that needed adrenaline and hospital care. They include a severe whole-body inflammatory response that needed hospital care. Others are itching, a racing heart, pain, sweating, poor sleep, blurred vision, extreme tiredness, flu-like illness, joint pain and skin sensitivity. Some people had muscle and tendon injuries, such as plantar fasciitis and Achilles tendinitis. Some products were of poor quality. The advisory names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples. The text read does not name ipamorelin. So the list is not a rate for ipamorelin (TGA, 13 April 2026).
That makes this a record about a category, not a rate for ipamorelin. The TGA says it has not assessed unapproved peptide products for safety, quality or effectiveness. It says important information about them is still unknown. Peptide side effects in general covers the wider evidence.
Comparison
Adverse events in the Phase 2 surgery trial NCT00672074, in 114 analysed bowel-surgery patients, as reported in the FDA's 2024 briefing document and the trial's abstract (Beck et al., 2014). Percentages are of those patients. This one small trial in one group of patients cannot separate a drug effect from surgery. It is not a rate for anyone else.
| Event | Result in the Phase 2 surgery trial, with its model, limit and source |
|---|---|
| Any treatment-emergent adverse event | 87.5 percent of patients given the drug and 94.8 percent given placebo. The authors said most events were mild to moderate. This trial cannot separate a drug effect from surgery (Beck et al., 2014). |
| Low potassium (hypokalaemia) | 12.5 percent of patients given the drug and 3.4 percent given placebo. It was more common with the drug in this one trial. This trial cannot separate a drug effect from surgery (Beck et al., 2014; FDA 2024). |
| Sleeplessness (insomnia) | 10.7 percent of patients given the drug and 5.2 percent given placebo. It was more common with the drug in this one trial. This trial cannot separate a drug effect from surgery (Beck et al., 2014; FDA 2024). |
| High blood sugar at discharge | 14.3 percent of patients given the drug and 8.6 percent given placebo. It was more common with the drug in this one trial. This trial cannot separate a drug effect from surgery (Beck et al., 2014; FDA 2024). |
| Nausea, vomiting, abdominal swelling | The most common events in both groups. They were similar between groups and numerically lower with the drug. This trial cannot separate a drug effect from surgery (Beck et al., 2014). |
| Serious adverse events | 17.9 percent (10 patients) given the drug and 15.5 percent (9 patients) given placebo. They included infection, anastomotic leak and readmission. The cause of each event is uncertain. This trial cannot separate a drug effect from surgery (FDA 2024, on Beck et al., 2014). |
| Infection | 10.7 percent given the drug and 10.3 percent given placebo, six patients in each group. The cause is uncertain. This trial cannot separate a drug effect from surgery (FDA 2024, on Beck et al., 2014). |
| Anastomotic leak | 3.6 percent (two patients) given the drug and 1.7 percent (one patient) given placebo. The counts are very small and the cause is uncertain. This trial cannot separate a drug effect from surgery (FDA 2024, on Beck et al., 2014). |
| Readmission within 30 days | 12.5 percent (seven patients) given the drug and 8.6 percent (five patients) given placebo. The cause is uncertain. This trial cannot separate a drug effect from surgery (FDA 2024, on Beck et al., 2014). |
| Deaths | Two patients given the drug died. The FDA summary gives no placebo-group count. The FDA said it is unclear whether the deaths were related to the drug. This trial cannot separate a drug effect from surgery (FDA 2024, on Beck et al., 2014). |
| Stopped treatment for an adverse event | Three patients in each group stopped treatment because of an adverse event. The FDA briefing document lists the reasons. This trial cannot separate a drug effect from surgery (FDA 2024, on Beck et al.). |
FAQ
What are the side effects of ipamorelin?
The one trial with adverse-event data had 114 bowel-surgery patients. They had more low potassium, sleeplessness and high blood sugar at discharge with the drug than with placebo. Two patients given the drug died after surgical complications. The trial was small. It cannot separate a drug effect from surgery (Beck et al., International Journal of Colorectal Disease, 2014; FDA 2024). The records opened for this page outside that trial are sparse.
Is ipamorelin safe?
The sources opened for this page do not establish safety. The FDA said the nonclinical toxicity studies were too limited. It found no safety data for giving it under the skin (the subcutaneous route). It lists ipamorelin acetate in category 2 as a possible major safety risk (FDA 2024; FDA category 2 page).
Is ipamorelin safer than HGH?
No comparison was found in the sources read for this page. In pigs ipamorelin did not raise ACTH or cortisol above the GHRH level. This is an animal result with no count in the abstract. It does not show a human result (Raun et al., 1998). The FDA could not conclude that ipamorelin avoids concerns seen with approved products that raise growth hormone. These concerns include glucose intolerance and diabetes (FDA 2024).
Did anyone die in the ipamorelin trial?
Yes. In the Phase 2 trial in 114 patients, two patients given the drug died. Both had bowel resection for colon cancer and then had complications. The FDA said it is unclear whether the deaths were related to the drug. One small trial after surgery cannot separate a drug effect from surgery (FDA 2024, on Beck et al., 2014).
What are the side effects of a tesamorelin and ipamorelin blend?
No study of the blend was found in the PubMed and registry searches of 14 October 2026. The Egrifta WR label, revised March 2025, lists joint pain, pain in the limbs and peripheral swelling among tesamorelin's most commonly reported adverse reactions. The numbers on adverse events found for ipamorelin in these searches come from the small trial in 114 patients (Beck et al., 2014).
Why did the FDA put ipamorelin in category 2?
The FDA cites the risk of an immune reaction from clumping or impurities. It cites unnatural amino acids that make the compound hard to describe fully. It also cites a published study. In it, patients with gut movement problems got ipamorelin into a vein. The trial figures from 114 patients are in the sections above (FDA category 2 page, 22 April 2026).
Where can I read about legality?
Is ipamorelin legal in Australia? sets out the Poisons Standard, TGA, FDA and WADA records with dates.
More in this hub
Citations
6 sourcesBeck DE et al. International Journal of Colorectal Disease. 2014;29(12):1527-1534.
doi:10.1007/s00384-014-2030-8Gobburu JV et al. Pharmaceutical Research. 1999;16(9):1412-1416.
doi:10.1023/a:1018955126402Raun K et al. European Journal of Endocrinology. 1998;139(5):552-561.
doi:10.1530/eje.0.1390552Falutz J et al. New England Journal of Medicine. 2007;357(23):2359-2370.
doi:10.1056/NEJMoa072375Sinha DK et al. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159.
doi:10.21037/tau.2019.11.30Dominikowski A et al. Frontiers in Endocrinology. 2026;17:1822475.
doi:10.3389/fendo.2026.1822475
Continue
CJC-1295 and ipamorelin blend reference materialResearch use only: not for human or animal use.
Read the CJC-1295 and ipamorelin research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
